Login to Your Account


Other News To Note


Wednesday, February 6, 2013
• AiCuris GmbH, of Wuppertal, Germany, said it achieved more than 50 percent patient enrollment in the second efficacy trial of herpes simplex virus (HSV) drug pritelivir (formerly AIC316). The study is comparing the potency of pritelivir to valacyclovir in reducing genital HSV shedding.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription


»

Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
 
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
 
Privacy Policy | Terms of Use
 
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2013 Thomson Reuters. Reproduction, reposting content is strictly prohibited.

Free Ezine

Sign up for Highlights FREE e-mail newsletter

Click here